Intellia $NTLA says CRISPR therapy shows superior gain for cardiomyopathy patients
Data suggests its gene-editing drug may outperform conventional drugs, but longer study needed $ALNY $BBIO #AHA24
www.statnews.com/2024/11/16/a...
Data suggests its gene-editing drug may outperform conventional drugs, but longer study needed $ALNY $BBIO #AHA24
www.statnews.com/2024/11/16/a...
Intellia says CRISPR therapy shows superior gain for cardiomyopathy patients
Intellia says its CRISPR treatment outperformed more conventional drugs for ATTR cardiomyopathy.
www.statnews.com
November 16, 2024 at 3:27 PM
Intellia $NTLA says CRISPR therapy shows superior gain for cardiomyopathy patients
Data suggests its gene-editing drug may outperform conventional drugs, but longer study needed $ALNY $BBIO #AHA24
www.statnews.com/2024/11/16/a...
Data suggests its gene-editing drug may outperform conventional drugs, but longer study needed $ALNY $BBIO #AHA24
www.statnews.com/2024/11/16/a...
It blows my mind what we're learning to do with our own bodies. New gene editing therapy for hereditary angioedema (severe swelling attacks) just got FDA priority review. In trials, it cut attacks by 87%. Imagine going from 10 attacks to just one a year. That's life-changing!
FDA Grants Priority Review to Intellia's CRISPR Therapy for Hereditary Angioedema
The U.S. Food and Drug Administration (FDA) has accepted Intellia Therapeutics' application for lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR-Cas gene-editing therapy, and granted it priority rev
crisprmedicinenews.com
September 27, 2026 at 8:03 AM
It blows my mind what we're learning to do with our own bodies. New gene editing therapy for hereditary angioedema (severe swelling attacks) just got FDA priority review. In trials, it cut attacks by 87%. Imagine going from 10 attacks to just one a year. That's life-changing!
Intellia gets FDA nod to resume one gene therapy trial after safety pause reut.rs/49H2U6Y
Intellia gets FDA nod to resume one gene therapy trial after safety pause
Intellia Therapeutics said on Tuesday that the U.S. drug regulator has lifted a clinical hold on one of its late-stage gene therapy trials, allowing the company to resume testing its experimental drug for a rare nerve disease.
reut.rs
January 27, 2026 at 7:01 PM
Intellia gets FDA nod to resume one gene therapy trial after safety pause reut.rs/49H2U6Y
La jueza del caso Mangione posee acciones de la industria sanitaria privada
https://spanishrevolution.net/jueza-caso-mangiione-acciones-industria-sanitaria/
Tiene entre 50.000 y 100.000 dólares en acciones de Pfizer y participa en inversiones dentro de otros gigantes del sector como Abbott Laborat…
https://spanishrevolution.net/jueza-caso-mangiione-acciones-industria-sanitaria/
Tiene entre 50.000 y 100.000 dólares en acciones de Pfizer y participa en inversiones dentro de otros gigantes del sector como Abbott Laborat…
La jueza del caso Mangione posee acciones de la industria sanitaria privada
Tiene entre 50.000 y 100.000 dólares en acciones de Pfizer y participa en inversiones dentro de otros gigantes del sector como Abbott Laboratories, Viatris e Intellia Therapeutics.
spanishrevolution.net
January 29, 2025 at 4:00 PM
La jueza del caso Mangione posee acciones de la industria sanitaria privada
https://spanishrevolution.net/jueza-caso-mangiione-acciones-industria-sanitaria/
Tiene entre 50.000 y 100.000 dólares en acciones de Pfizer y participa en inversiones dentro de otros gigantes del sector como Abbott Laborat…
https://spanishrevolution.net/jueza-caso-mangiione-acciones-industria-sanitaria/
Tiene entre 50.000 y 100.000 dólares en acciones de Pfizer y participa en inversiones dentro de otros gigantes del sector como Abbott Laborat…
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.
cnb.cx
April 27, 2026 at 11:14 AM
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
🧪 Hiring Alert--At last some good news!: 9 top Biotech & Pharma companies are hiring in Massachusetts, including Moderna, Takeda, Intellia, & more. Roles range from scientists to directors—remote too! Check out the latest openings in the Genetown hub. 🧬🔬 #LifeSciences #Jobs #Hiring #STEM.
9 Companies Hiring in Massachusetts
Looking for a biopharma job in Massachusetts? Check out the BioSpace list of nine companies hiring life sciences professionals like you.
www.biospace.com
April 18, 2025 at 1:01 AM
🧪 Hiring Alert--At last some good news!: 9 top Biotech & Pharma companies are hiring in Massachusetts, including Moderna, Takeda, Intellia, & more. Roles range from scientists to directors—remote too! Check out the latest openings in the Genetown hub. 🧬🔬 #LifeSciences #Jobs #Hiring #STEM.
scientists just wrapped a phase 3 trial where in vivo crispr (gene editing directly inside the body!) cut hereditary angioedema attacks by 87%. 62% of patients were attack-free for 6 months. this means a major improvement for people with this rare inherited disease.
World's First In Vivo CRISPR Gene Editing Therapy Succeeds in Phase 3 Trial for Hereditary Angioedem
Intellia Therapeutics has announced groundbreaking positive results from its Phase 3 HAELO trial for lonvoguran ziclumeran (lonvo-z), a one-time CRISPR-based treatment for hereditary angioedema (HAE).
crisprmedicinenews.com
June 20, 2026 at 8:00 PM
scientists just wrapped a phase 3 trial where in vivo crispr (gene editing directly inside the body!) cut hereditary angioedema attacks by 87%. 62% of patients were attack-free for 6 months. this means a major improvement for people with this rare inherited disease.
Why do editing for a disease if there are repeat treatments such as biologics, RNAi, ASOs?
Et voila (see also their NEJM paper).
@jasonmast.bsky.social
www.statnews.com/2024/11/16/a...
Et voila (see also their NEJM paper).
@jasonmast.bsky.social
www.statnews.com/2024/11/16/a...
Intellia says CRISPR therapy shows superior gain for cardiomyopathy patients
Intellia says its CRISPR treatment outperformed more conventional drugs for ATTR cardiomyopathy.
www.statnews.com
November 18, 2024 at 1:16 AM
Why do editing for a disease if there are repeat treatments such as biologics, RNAi, ASOs?
Et voila (see also their NEJM paper).
@jasonmast.bsky.social
www.statnews.com/2024/11/16/a...
Et voila (see also their NEJM paper).
@jasonmast.bsky.social
www.statnews.com/2024/11/16/a...
"Intellia Therapeutics announced that its systemic CRISPR–Cas9 gene editing medicine had met primary and secondary endpoints, leading the biotech to start a rolling submission for US Food and Drug Administration approval"
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Intellia heads to FDA with first in vivo CRISPR-based gene editing therapy - Nature Biotechnology
Nature Biotechnology - Intellia heads to FDA with first in vivo CRISPR-based gene editing therapy
www.nature.com
May 20, 2026 at 6:18 AM
"Intellia Therapeutics announced that its systemic CRISPR–Cas9 gene editing medicine had met primary and secondary endpoints, leading the biotech to start a rolling submission for US Food and Drug Administration approval"
www.nature.com/articles/s41...
www.nature.com/articles/s41...
In Brief: The most advanced clinical trial for an in vivo gene editor, @intelliatx.bsky.social's lonvoguran ziclumeran (lonvo-z), reported positive phase 3 results in hereditary angioedema www.nature.com/articles/s41...
Intellia heads to FDA with first in vivo CRISPR-based gene editing therapy - Nature Biotechnology
Nature Biotechnology - Intellia heads to FDA with first in vivo CRISPR-based gene editing therapy
www.nature.com
May 22, 2026 at 3:05 PM
In Brief: The most advanced clinical trial for an in vivo gene editor, @intelliatx.bsky.social's lonvoguran ziclumeran (lonvo-z), reported positive phase 3 results in hereditary angioedema www.nature.com/articles/s41...
WHAT...A...WEEK!
Landmark ATTR-Polyneuropathy Data by Intellia Caps Off Momentous Week in #CRISPR Therapeutics (blog): rnaitherapeutics.blogspot.com/2025/05/land...
#CPS1 #Musunuru $NTLA $PRME $VERV $BEAM $PRQR
Landmark ATTR-Polyneuropathy Data by Intellia Caps Off Momentous Week in #CRISPR Therapeutics (blog): rnaitherapeutics.blogspot.com/2025/05/land...
#CPS1 #Musunuru $NTLA $PRME $VERV $BEAM $PRQR
Landmark ATTR-Polyneuropathy Data by Intellia Caps Off Momentous Week in CRISPR Therapeutics
This has been a most remarkable week in CRISPR Therapeutics as momentum continues to build. Bespoke therapeutic in 6 months First, the ...
rnaitherapeutics.blogspot.com
May 18, 2025 at 4:19 PM
WHAT...A...WEEK!
Landmark ATTR-Polyneuropathy Data by Intellia Caps Off Momentous Week in #CRISPR Therapeutics (blog): rnaitherapeutics.blogspot.com/2025/05/land...
#CPS1 #Musunuru $NTLA $PRME $VERV $BEAM $PRQR
Landmark ATTR-Polyneuropathy Data by Intellia Caps Off Momentous Week in #CRISPR Therapeutics (blog): rnaitherapeutics.blogspot.com/2025/05/land...
#CPS1 #Musunuru $NTLA $PRME $VERV $BEAM $PRQR
Intellia plays down concerns about accidental germline transmission in CRISPR trial
www.statnews.com/2023/08/21/i...
www.statnews.com/2023/08/21/i...
Intellia plays down concerns about accidental germline transmission in CRISPR trial
Over the weekend, Intellia sought to address concerns in the gene editing community about accidental germline transmission.
www.statnews.com
August 21, 2023 at 5:37 PM
Intellia plays down concerns about accidental germline transmission in CRISPR trial
www.statnews.com/2023/08/21/i...
www.statnews.com/2023/08/21/i...
Intellia (#$NTLA): FDA Accepts Lonvo-z BLA with Priority Review, PDUFA March 10, 2027
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/intellia-the...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/intellia-the...
September 23, 2026 at 6:20 PM
Intellia (#$NTLA): FDA Accepts Lonvo-z BLA with Priority Review, PDUFA March 10, 2027
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/intellia-the...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/intellia-the...
Intellia traced the worst liver enzyme spikes in its CRISPR ATTR trials to a single genetic marker, giving it a way to flag at-risk patients before dosing.
Intellia says it has found a key clue to its gene editing safety issues
Intellia Therapeutics said it discovered a common link among the patients who faced the highest liver enzyme elevations after receiving its CRISPR gene editing treatment for ATTR amyloidosis.
endpoints.news
August 6, 2026 at 5:30 PM
Intellia traced the worst liver enzyme spikes in its CRISPR ATTR trials to a single genetic marker, giving it a way to flag at-risk patients before dosing.
Intellia Tx's positive results from Phase 2 trial for its CRISPR- based therapy for hereditary angioedema (in NEJM paper below) & the editorial naming it as a milestone for gene-editing therapies are included in editors' picks showcasing the most significant contributions to clinical medicine in '24
This year's edition of our annual Notable Articles collection, selected by NEJM editors, showcases the most significant contributions to clinical medicine and patient care. Download the collection: nej.md/4gHiO1V
#MedSky
#MedSky
December 30, 2024 at 9:32 PM
Intellia Tx's positive results from Phase 2 trial for its CRISPR- based therapy for hereditary angioedema (in NEJM paper below) & the editorial naming it as a milestone for gene-editing therapies are included in editors' picks showcasing the most significant contributions to clinical medicine in '24
fda's reviewing a crispr gene-editing therapy for hereditary angioedema (hae). it reduced swelling attacks by 87% after a single dose, with 62% of patients attack-free. how many more conditions will we see addressed this way?
FDA Grants Priority Review to Intellia's CRISPR Gene-Editing Therapy for Hereditary Angioedema
Intellia Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) and granted Priority Review for lonvoguran ziclumeran (lonvo-z). T
allsci.com
September 13, 2026 at 2:02 AM
fda's reviewing a crispr gene-editing therapy for hereditary angioedema (hae). it reduced swelling attacks by 87% after a single dose, with 62% of patients attack-free. how many more conditions will we see addressed this way?
«Tesla in molti settori è all’avanguardia»
Interessanti anche Intellia Therapeutics, per il suo lavoro pionieristico nell’editing genetico e Coinbase, operatore dominant...
https://www.ilsole24ore.com/art/tesla-molti-settori-e-all-avanguardia-AG9fsxKB
Interessanti anche Intellia Therapeutics, per il suo lavoro pionieristico nell’editing genetico e Coinbase, operatore dominant...
https://www.ilsole24ore.com/art/tesla-molti-settori-e-all-avanguardia-AG9fsxKB
November 30, 2024 at 3:05 PM
«Tesla in molti settori è all’avanguardia»
Interessanti anche Intellia Therapeutics, per il suo lavoro pionieristico nell’editing genetico e Coinbase, operatore dominant...
https://www.ilsole24ore.com/art/tesla-molti-settori-e-all-avanguardia-AG9fsxKB
Interessanti anche Intellia Therapeutics, per il suo lavoro pionieristico nell’editing genetico e Coinbase, operatore dominant...
https://www.ilsole24ore.com/art/tesla-molti-settori-e-all-avanguardia-AG9fsxKB
A one-time CRISPR treatment dramatically reduced attacks in hereditary angioedema, marking a major milestone for genetic medicine.
Link as first comment.
#longevity #geneediting #crispr #geneticmedicine #biotech
Link as first comment.
#longevity #geneediting #crispr #geneticmedicine #biotech
June 19, 2026 at 4:25 PM
A one-time CRISPR treatment dramatically reduced attacks in hereditary angioedema, marking a major milestone for genetic medicine.
Link as first comment.
#longevity #geneediting #crispr #geneticmedicine #biotech
Link as first comment.
#longevity #geneediting #crispr #geneticmedicine #biotech
$NTLA +19% [Intellia completed enrollment for lonvo-z, a gene-editing drug for severe swelling (HAE). It aims to be the first one-time treatment for HAE, a rare genetic disease. Top study data is expected in early 2026, with a potential U.S. launch in early 2027.] notreload.xyz/intellia-ang...
Intellia's Angioedema Drug: Enrollment Complete, Shares Soar
Intellia completed enrollment for lonvo-z, a gene-editing drug for severe swelling (HAE). It aims to be the first one-time treatment for HAE, a rare genetic disease. Top study data is expected in earl...
notreload.xyz
September 18, 2025 at 4:10 PM
$NTLA +19% [Intellia completed enrollment for lonvo-z, a gene-editing drug for severe swelling (HAE). It aims to be the first one-time treatment for HAE, a rare genetic disease. Top study data is expected in early 2026, with a potential U.S. launch in early 2027.] notreload.xyz/intellia-ang...
🔬🧬 A one-time in vivo CRISPR treatment cut hereditary angioedema attacks by 87% in a Phase 3 trial (weeks 5–28). https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-additional-positive-phase-3 #OnlyGoodNews
June 17, 2026 at 1:34 PM
🔬🧬 A one-time in vivo CRISPR treatment cut hereditary angioedema attacks by 87% in a Phase 3 trial (weeks 5–28). https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-additional-positive-phase-3 #OnlyGoodNews
Nexiguran ziclumeran from Intellia is exactly this!
May 26, 2026 at 9:14 PM
Nexiguran ziclumeran from Intellia is exactly this!
Imagine reducing a life-threatening condition's attacks by 87%! This groundbreaking CRISPR treatment not only delivers impressive results but does so by editing genes directly in the body. Could this be the future of medicine? 🤯
CRISPR Inside the Human Body Passes Phase 3: 87% Fewer Hereditary Angioedema Attacks - Sinaptica
A historic milestone for gene medicine
Intellia Therapeutics has just published the results of its Phase 3 HAELO trial with lonvoguran ziclumeran (lonvo-z), a C
sinapti.ca
April 27, 2026 at 2:13 PM
Imagine reducing a life-threatening condition's attacks by 87%! This groundbreaking CRISPR treatment not only delivers impressive results but does so by editing genes directly in the body. Could this be the future of medicine? 🤯
Caribou Biosciences - Jan 2011
Editas Medicine - November 2013
Intellia Therapeutics - November 2014
Editas Medicine - November 2013
Intellia Therapeutics - November 2014
December 12, 2024 at 11:33 PM
Caribou Biosciences - Jan 2011
Editas Medicine - November 2013
Intellia Therapeutics - November 2014
Editas Medicine - November 2013
Intellia Therapeutics - November 2014
Intellia Therapeutics resumes Phase 3 clinical trial for a gene editing therapy targeting heart disease linked to misfolded proteins after FDA lifted hold.
🔗 Source: https://endpoints.news/fda-lifts-hold-on-second-intellia-phase-3-gene-editing-trial/
🔗 Source: https://endpoints.news/fda-lifts-hold-on-second-intellia-phase-3-gene-editing-trial/
August 9, 2026 at 3:48 AM
Intellia Therapeutics resumes Phase 3 clinical trial for a gene editing therapy targeting heart disease linked to misfolded proteins after FDA lifted hold.
🔗 Source: https://endpoints.news/fda-lifts-hold-on-second-intellia-phase-3-gene-editing-trial/
🔗 Source: https://endpoints.news/fda-lifts-hold-on-second-intellia-phase-3-gene-editing-trial/